CYTOSORBENTS CORPORATION Restricted Cash
CYTOSORBENTS CORPORATION (CTSO) had Restricted Cash of $6.50 million as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCash · last filed 2025-03-31
- 2024-12-31: Restricted Cash $6.50M.
| Period end | Restricted Cash |
|---|---|
| 2024-12-31 | $6.50M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |